Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NASDAQ | Common Stock
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States.
The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications.
The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC.
Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 24 | -0.26 Increased by 0.00% | -0.22 Decreased by -18.18% |
| May 7, 24 | -0.70 Decreased by -79.49% | -0.19 Decreased by -268.42% |
| Mar 11, 24 | -0.35 Decreased by -45.83% | -0.30 Decreased by -16.67% |
| Nov 7, 23 | -0.17 Increased by +45.16% | -0.29 Increased by +41.38% |
| Aug 7, 23 | -0.26 Decreased by -4.00% | -0.30 Increased by +13.33% |
| May 8, 23 | -0.39 Decreased by -143.75% | -0.26 Decreased by -50.00% |
| Mar 6, 23 | -0.24 Decreased by -380.00% | -0.25 Increased by +4.00% |
| Nov 7, 22 | -0.31 Decreased by -1.13 K% | -0.24 Decreased by -29.17% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 15.43 M Increased by +3.18% | -36.49 M Decreased by -6.97 K% | Decreased by -236.58% Decreased by -6.75 K% |
| Jun 30, 24 | 16.44 M Increased by +8.26% | -43.78 M Decreased by -111.67% | Decreased by -266.27% Decreased by -95.51% |
| Mar 31, 24 | 14.71 M Increased by +10.03% | -64.85 M Decreased by -78.16% | Decreased by -440.69% Decreased by -61.93% |
| Dec 31, 23 | 14.80 M Increased by +5.16% | -29.22 M Decreased by -149.25% | Decreased by -197.41% Decreased by -137.03% |
| Sep 30, 23 | 14.95 M Increased by +24.95% | -516.00 K Increased by +98.08% | Decreased by -3.45% Increased by +98.46% |
| Jun 30, 23 | 15.19 M Increased by +23.81% | -20.68 M Decreased by -17.40% | Decreased by -136.19% Increased by +5.17% |
| Mar 31, 23 | 13.37 M Increased by +1.42% | -36.40 M Decreased by -401.97% | Decreased by -272.15% Decreased by -394.95% |
| Dec 31, 22 | 14.08 M Increased by +14.36% | -11.72 M Decreased by -111.99% | Decreased by -83.28% Decreased by -85.36% |